Drug
Torvutatug Samrotecan
Torvutatug Samrotecan: highest development phase Phase 3, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| Torvutatug samrotecan NCT07851025 | Phase 3 | Epithelial Ovarian Cancer |
Latest
No recent events.
Follow Torvutatug Samrotecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.